However, despite almost 20 years since it is discovery by Kojima and colleagues, no specific ghrelin targeting anti-obesity drug or cachexia therapeutics are on the market for clinical use [2]. Here, GHRL is linked to obesity due to melanocortin 4 receptor deficiency.